Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 16/20 | 0.45 |
| ▸ | CNR1 | P21554 | 15/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21485548 | 0.96 | CNR2 (0.44) | CNR2CNR1FAAHHRH3EPHX2 | |
| SCHEMBL21506753 | 0.95 | CNR2 (0.42) | CNR2CNR1FAAHHRH3EPHX2 | |
| SCHEMBL21458182 | 0.90 | CNR2 (0.40) | CNR2CNR1FAAHHRH3 | |
| SCHEMBL31203084 | 0.89 | PTGER4 (0.39) | CNR2CNR1FAAHHRH3 | |
| SCHEMBL21458130 | 0.89 | PTGER4 (0.39) | CNR2CNR1FAAHHRH3 | |
| SCHEMBL21485567 | 0.88 | S1PR3 (0.41) | CNR2CNR1HRH3 | |
| SCHEMBL21506750 | 0.87 | CNR2 (0.42) | CNR2CNR1FAAHHRH3EPHX2 | |
| SCHEMBL31203184 | 0.86 | CNR2 (0.42) | CNR2CNR1FAAHHRH3 | |
| SCHEMBL31203180 | 0.85 | CNR2 (0.42) | CNR2CNR1FAAHHRH3 | |
| SCHEMBL21481745 | 0.85 | CNR2 (0.39) | CNR2CNR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024491-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024491-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | CNR2 3/4885CNR1 6/4885FAAH 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.